Education
Originally posted on ALS.org | April 25, 2023 Washington, D.C. (April 25. 2023) – The ALS Association commends the FDA for approving tofersen under the agency’s accelerated approval pathway for the treatment of people living with ALS connected to mutations in the SOD1 gene. This marks the first time the FDA has approved a treatment for ALS…
Originally posted on ALS.org | March 16, 2023 The U.S. House and Senate are preparing legislation that determines how much will be spent on research. It’s important that ALS research requests are at the top of the “must have” lists for appropriations. To do that, we need as many members as possible of the House…
Originally posted on ALS.org | March 8, 2023 The ALS Association submitted comments today to the FDA’s Central and Peripheral Nervous System Advisory Committee, urging it to recommend approval of tofersen for people with ALS linked to a SOD1 gene mutation. The committee will meet virtually on March 22 to review data associated with Biogen’s new drug…